<DOC>
	<DOC>NCT02183194</DOC>
	<brief_summary>The purpose of this study is to evaluate the Lutonix® 035 Drug Coated Balloon PTA Catheter (CE mark) for use as intended in the treatment of subjects with clinically significant hemodialysis vascular access stenosis or occlusion.</brief_summary>
	<brief_title>Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and Grafts</brief_title>
	<detailed_description />
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Arteriovenous Fistula</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1. Age ≥18 years 2. The subject is legally competent, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the informed consent form (ICF) 3. Hemodialysis access on the arm presenting with any clinical abnormalities as defined in the K/DOQI guidelines 4. Native AV fistula or synthetic AV graft has been implanted ≥30 days 5. Target de novo or nonstented restenotic lesion(s) consisting of a &gt;50% stenosis by visual estimate. Successful treatment of non target lesion(s) (residual stenosis &lt;30% by visual estimate) without procedural complication by standard of care 6. Successful predilatation of the target lesion with a percutaneous transluminal angioplasty (PTA) balloon 7. Intended target lesion(s) (maximum of 2) can be treated 8. No other prior surgical or vascular interventions within 2 weeks before and/or planned 30 days after the treatment 1. Women who are pregnant, lactating, or planning on becoming pregnant or men intending to father children 2. Known contraindication (including allergic reaction) or sensitivity to contrast media, ASA, clopidogrel, ticlopidine, paclitaxel (mild to severe cases), that cannot be adequately managed with preand postprocedure medication 3. Life expectancy &lt;12months 4. Scheduled for kidney transplant or peritoneal dialysis in the next 12months; 5. Thrombosed access 6. Stent in the target treatment area 7. Blood coagulative disorder, sepsis, or current AV access infection 8. Currently participating in an investigational drug, biologic, or device study, or previous enrollment in this study NOTE: Enrollment in another investigational drug, biologic, or device study during the follow up period is not allowed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>